

1 **Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and**
2 **vaccine trials**

3

4 Anton M. Sholukh^{1*#}, Andrew Fiore-Gartland^{1*}, Emily S. Ford^{1,3}, Yixuan J. Hou⁵, Victor Tse⁵, Hannah
5 Kaiser⁷, Arnold Park⁷, Florian A. Lempp⁷, Russell Saint Germain¹, Emily Bossard¹, Jia Jin Kee¹, Kurt
6 Diem⁴, Andrew B. Stuart¹, Peter B. Rupert², Chance Brock², Matthew Buerger², Margaret K. Doll¹⁰, April
7 Kaur Randhawa¹, Leonidas Stamatatos¹, Roland K. Strong^{1,2}, Colleen McLaughlin¹⁰, Keith R.
8 Jerome^{1,4}, Ralph S. Baric^{5,6}, David Montefiori^{8,9}, and Lawrence Corey^{1,3,4#}

9

10 **Supplementary materials**


11

12 Supplementary Table 1. Symptoms reported by study participants

Symptom	Yes	No	Missing	Percent reporting symptom
fever	23	11	6	57.5
chills	26	10	4	65
fatigue	35	4	1	87.5
myalgia	27	9	4	67.5
sore throat	20	14	6	50
cough	29	6	5	72.5
rhinorrhea	24	10	6	60
dyspnea	22	13	5	55
wheezing	6	19	15	15
chest pain	13	16	11	32.5
other respiratory	8	17	15	20
headache	27	8	5	67.5
nausea	9	18	13	22.5
abdominal pain	6	20	14	15
diarrhea	14	16	10	35
loss senses	26	8	6	65
eye pain	7	19	14	17.5
rash feet	2	21	17	5
rash body	4	21	15	10


13

14 **A**



15

16 **B**



17

18


19 Supplementary Figure 1. Neutralizing antibody assay with SARS-CoV-2-nLuc in Vero E6 cells (A) and
20 with PsVSV-Luc-D19 in Vero cells (B).

21

22


23

24 **A**



25

26 **B**




27

28

29 Supplementary Figure 2. Neutralizing antibody assay with LV-pseudovirus in 293T/ACE2 cells (A) and

30 with LV-pseudovirus in T2M-bl/ACE2/TMPRSS2 cells (B).


31 **A**



32

33

34 **B**



35


36 Supplementary Figure 3. Surrogate virus neutralization test from GenScript. A, samples tested in 1:10

37 dilution as per manufacturer protocol. Dotted lines show 50 and 20% neutralization, respectively.

38 Twenty percent is suggested as positivity cutoff by the manufacturer; B, plasma samples were titrated

39 2-fold starting at 1:10 to impute ND50 titers.


40



41

42 Supplementary Figure 4. Comparison of ND50 (A) and ND80 (B) titers measured in cell-based assays

43



44


45 Supplementary Figure 5. Pseudovirus assays but not live virus assay allows reliable ND80
 46 measurement. Geometric mean ND50 and ND80 for the corresponding assay are shown underneath
 47 each graph

48 Supplementary Table 2. Fold change between ND50 and ND80 values

Neutralization	Mean ND fold change [95% CI]	P-value
SARS-CoV-2/Vero E6	1.954 [1.62, 2.29]	<0.0001
LV-pseudovirus/293T	4.573 [3.65, 5.5]	<0.0001
LV-pseudovirus/TZM-bl	4.478 [3.48, 5.48]	<0.0001
PsVSV-Luc-D19/Vero	2.967 [2.7, 3.24]	<0.0001

49

50




52

53

54 Supplementary Figure 6. Pearson correlation model analysis of ND50 titers among neutralization
 55 assays.

56



— Linear model

57

58 Supplementary Figure 7. Pearson correlation model analysis of ND50 titers vs SARS-CoV-2 specific

59 IgG concentration in plasma samples.